PT  - JOURNAL ARTICLE
AU  - Buonaccorsi, John P.
TI  - On the Effects of Misclassification in Estimating Efficacy With Application to Recent COVID-19 Vaccine Trials
AID  - 10.1101/2020.12.04.20244244
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.04.20244244
4099  - http://medrxiv.org/content/early/2021/04/02/2020.12.04.20244244.short
4100  - http://medrxiv.org/content/early/2021/04/02/2020.12.04.20244244.full
AB  - The recent trials for proposed COVID-19 vaccines have garnered a considerable amount of attention and as of this writing extensive vaccination efforts are underway. The first two vaccines approved in the United States are the Moderna and Pfizer vaccines both with estimated efficacy near 95%. One question which has received limited attention, and which we address here, is what affect false positives or false negatives have on the estimated efficacy. Expressions for potential bias due to misclassification of COVID status are developed as are general formulas to adjust for misclassification, allowing for either differential or non-differential misclassification. These results are illustrated with numerical investigations pertinent to the Moderna and Pfizer trials. The general conclusion, fortunately, is that the potential misclassification of COVID status almost always would lead to underestimation of the efficacy and that correcting for false positives or negatives will typically lead to even higher estimated efficacy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB oversight involvedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData taken off web and public press reporting COVID-19 vaccine trials by Moderna and Pfizer